ReviewDie Naturwissenschaften2026
Comprehensive analysis of the pharmacological potentials of Marrubium vulgare (white horehound): a recent overview of phytochemistry and biological activities.
Review in Die Naturwissenschaften, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marrubium vulgare L. (M. vulgare) is a medicinal plant widely employed in traditional medicine for the management of respiratory, gastrointestinal, cardiovascular, and inflammatory disorders. Owing to its broad ethnopharmacological applications and rich phytochemical composition, the plant has attracted increasing scientific attention. This review summarizes current knowledge regarding the phytochemistry, traditional uses, and biological activities of M. vulgare, with particular emphasis on marrubiin, its major bioactive diterpene. Available studies indicate that M. vulgare contains a diverse range of secondary metabolites, including diterpenoids, flavonoids, phenolic acids, tannins, and volatile constituents, many of which contribute to its pharmacological properties. Experimental investigations have reported antioxidant, anti-inflammatory, antimicrobial, antidiabetic, hepatoprotective, gastroprotective, cardioprotective, neuroprotective, and antiproliferative/cytotoxic activities. Among these constituents, marrubiin is one of the most extensively investigated compounds and may contribute to several of the reported biological effects. Collectively, the available preclinical evidence provides pharmacological support for several traditional uses of M. vulgare and identifies the plant as a source of compounds worthy of further investigation. However, most evidence is derived from in vitro and animal studies, while clinical data remain scarce. Considerable variability in extract composition and experimental protocols, together with limited information regarding pharmacokinetics, long-term safety, standardization, and mechanism-specific validation, currently restricts clinical interpretation. Further studies using chemically standardized preparations, rigorous mechanistic approaches, comprehensive toxicological assessment, and, where justified, well-designed clinical trials are required to establish the therapeutic relevance of M. vulgare and its major constituents.
Indexed as
Identifiers
42734823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.